Case Number 8587
Request Date 11/05/2022
Completion Date 19/05/2022

 

Details of the Request

1. How many patients were treated in the last 3 months by the Dermatology department (for any medical condition) with the following biologic drugs:

  • Adalimumab - Humira
  • Adalimumab Biosimilar
  • Apremilast
  • Bimekizumab
  • Brodalumab
  • Certolizumab
  • Dimethyl fumarate
  • Etanercept - Enbrel
  • Etanercept Biosimilar
  • Guselkumab
  • Infliximab - Remicade
  • Infliximab Biosimilar
  • Ixekizumab
  • Risankizumab
  • Secukinumab
  • Tildrakizumab
  • Ustekinumab

 

2. How many patients were treated in the last 3 months by the Gastroenterology department (for any medical condition) with the following biologic drugs:

  • Adalimumab - Humira
  • Adalimumab Biosimilar
  • Filgotinib
  • Golimumab
  • Infliximab - Remicade
  • Infliximab Biosimilar
  • Ozanimod
  • Tofacitinib
  • Ustekinumab
  • Vedolizumab

 

Details of the Response

Q1. How many patients were treated in the last 3 months by the Dermatology department (for any medical condition) with the following biologic drugs:

Adalimumab - Humira 14
Adalimumab Biosimilar 28
Apremilast 15
Bimekizumab 0
Brodalumab 0
Certolizumab 1
Dimethyl fumarate 1
Etanercept - Enbrel 0
Etanercept Biosimilar 0
Guselkumab 10
Infliximab - Remicade 0
Infliximab Biosimilar 0
Ixekizumab 1
Risankizumab 0
Secukinumab 21
Tildrakizumab 0
Ustekinumab 15

 

Q2. How many patients were treated in the last 3 months by the Gastroenterology department (for any medical condition) with the following biologic drugs:

Adalimumab - Humira 17
Adalimumab Biosimilar 81
Filgotinib 0
Golimumab 0
Infliximab - Remicade 1
Infliximab Biosimilar 86
Ozanimod 0
Tofacitinib 0
Ustekinumab 76
Vedolizumab 8

 

 

Protecting Your Online Privacy
Protecting Your Online Privacy

This Ashford and St Peter's website uses cookies to track visitor numbers. Find out more in our Cookies Policy and Privacy Policy. You can also read our Accessibility Statement and Privacy Notice for your information.